Induction of apoptosis by flavopiridol in human neuroblastoma cells is enhanced under hypoxia and associated with N-myc proto-oncogene down-regulation

Clinical Cancer Research

Volumn 10, Issue 24, 2004, Pages 8704-8719

  Puppo, Maura ^a   Pastorino, Sandra ^c   Melillo, Giovanni ^b   Pezzolo, Annalisa ^a   Varesio, Luigi ^a   Bosco, Maria Carla ^a  

^a G GASLINI INSTITUTE   (Italy)

^b SAIC FREDERICK INC   (United States)

^c NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CASPASE 2; CASPASE 3; CASPASE 8; CASPASE 9; CASPASE INHIBITOR; CYTOCHROME C; FLAVOPIRIDOL; GENOMIC DNA;

APOPTOSIS; ARTICLE; CELL GROWTH; CELL VIABILITY; CONTROLLED STUDY; CYTOTOXICITY; DNA CONTENT; DNA SYNTHESIS INHIBITION; DOSE TIME EFFECT RELATION; ENZYME ACTIVATION; FLOW CYTOMETRY; GENE EXPRESSION; GROWTH INHIBITION; HUMAN; HUMAN CELL; HYPOXIA; NEUROBLASTOMA; NEUROBLASTOMA CELL; NORTHERN BLOTTING; ONCOGENE C MYB; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTO ONCOGENE; SOUTHERN BLOTTING; WESTERN BLOTTING;

ANOXIA; APOPTOSIS; BROMODEOXYURIDINE; CASPASES; CELL HYPOXIA; CELL SURVIVAL; CYCLIN-DEPENDENT KINASES; CYTOCHROMES C; DNA; DOWN-REGULATION; ENZYME ACTIVATION; ENZYME INHIBITORS; FLAVONOIDS; G1 PHASE; G2 PHASE; GENES, MYC; GROWTH INHIBITORS; HUMANS; IN SITU NICK-END LABELING; NEUROBLASTOMA; PIPERIDINES; TETRAZOLIUM SALTS; THIAZOLES; TUMOR CELLS, CULTURED;

EID: 11144244272     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-03-0422     Document Type: Article

References (63)

1. Thiele CJ. Neuroblastoma. In Masters JRW, Palsson B, editors. Human cell culture. London, Great Britain: Kluwer Academic Publishers; 1999. p. 21-22.
2. Weinstein JL, Katzenstein HM, Cohn SL. Advances in the diagnosis and treatment of neuroblastoma. Oncologist 2003;8:278-92.
3. Bordow SB, Norris MD, Haber PS, Marshall GM, Haber M. Prognostic significance of MYCN oncogene expression in childhood neuroblastoma. J Clin Oncol 1998;16:3286-94.
4. Meitar D, Crawford E, Rademaker AW, Cohn SL. Tumor angiogenesis correlates with metastatic disease, N-myc amplification, and poor outcome in human neuroblastoma. J Clin Oncol 1996;14:405-14.
5. Ribatti D, Raffaghello L, Pastorino F, et al. In vivo angiogenic activity of neuroblastoma correlates with MYCN oncogene overexpression. Int J Cancer 2002;102:351-4.
6. Tonini GP, Boni L, Pession A, et al. MYCN oncogene amplification in neuroblastoma is associated with worse prognosis, except in stage 4s: the Italian experience with 295 children. J Clin Oncol 1997;15:85-93.
7. Matthay KK, Villablanca JG, Seeger RC, et al. Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-cis-retinoic acid. Children's Cancer Group. N Engl J Med 1999;341:1165-73.
8. Harris AL. Hypoxia-a key regulatory factor in tumour growth. Nat Rev Cancer 2002;2:38-47.
9. Semenza GL. HIF-1 and tumor progression: pathophysiology and therapeutics. Trends Mol Med 2002;8:S62-7.
10. Carmeliet P, Dor Y, Herbert JM, et al. Role of HIF-1α in hypoxia-mediated apoptosis, cell proliferation and tumor angiogenesis. Nature (Lond) 1998;394:485-90.
11. Carta L, Pastorino S, Melillo G, Bosco MC, Massazza S, Varesio L. Engineering of macrophages to produce IFN γ in response to hypoxia. J Immunol 2001;166:5374-80.
12. Melillo G, Musso T, Sica A, Tailor LS, Cox GW, Varesio L. A hypoxia-responsive element mediates a novel pathway of activation of the inducible nitric oxide synthase promoter. J Exp Med 1995;182:1683-93.
13. Melillo G, Sausville EA, Cloud K, Lahusen T, Varesio L, Senderovicz AM. Flavopiridol, a protein kinase inhibitor, down-regulates hypoxic induction of vascular endothelial growth factor expression in human monocytes. Cancer Res 1999;59:5433-7.
14. Jogi A, Ora I, Nilsson H, et al. Hypoxia alters gene expression in human neuroblastoma cells toward an immature and neural crest-like phenotype. Proc Natl Acad Sci USA 2002;99:7021-6.
15. Stolze I, Berchner-Pfannschmidt U, Freitag P, et al. Hypoxia-inducible erythropoietin gene expression in human neuroblastoma cells. Blood 2002;100:2623-8.
16. Lasorella A, Noseda M, Beyna M, Yokota Y, Iavarone A. Id2 is a retinoblastoma protein target and mediates signalling by Myc oncoproteins. Nature (Lond) 2000;407:592-8.
17. Rapella A, Negrioli A, Melillo G, Pastorino S, Varesio L, Bosco MC. Flavopiridol inhibits vascular endothelial growth factor production induced by hypoxia or picolinic acid in human neuroblastoma. Int J Cancer 2002;99:658-64.
18. Pastorino F, Brignole C, Marimpietri D, et al. Doxorubicin-loaded Fab' fragments of anti-disialoganglioside immunoliposomes selectively inhibit the growth and dissemination of human neuroblastoma in nude mice. Cancer Res 2003;63:86-92.
19. Ladenstein R, Philip T, Lasset C, et al. Multivariate analysis of risk factors in stage 4 neuroblastoma patients over the age of one year treated with megatherapy and stem-cell transplantation: a report from the European Bone Marrow Transplantation Solid Tumor Registry. J Clin Oncol 1998;16:953-65.
20. De Bernardi B, Nicolas B, Boni L, et al. Disseminated neuroblastoma in children older than one year at diagnosis: comparable results with three consecutive high-dose protocols adopted by the Italian Co-Operative Group for Neuroblastoma. J Clin Oncol 2003;21:1592-601.
21. Surico G, Muggeo P, De Leonardis F, Rigillo N. New paclitaxel-cisplatin based chemotherapy regimen for advanced stage, recurrent, or refractory neuroblastoma-preliminary report. Med Pediatr Oncol 2003;40:130-2.
22. Borriello A, Roberto R, Della RF, Iolascon A. Proliferate and survive: cell division cycle and apoptosis in human neuroblastoma. Haematologica 2002;87:196-214.
23. Eggert A, Grotzer MA, Zuzak TJ, et al. Resistance to tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis in neuroblastoma cells correlates with a loss of caspase-8 expression. Cancer Res 2001;61:1314-9.
24. Teitz T, Wei T, Valentine MB, et al. Caspase 8 is deleted or silenced preferentially in childhood neuroblastomas with amplification of MYCN. Nat Med 2000;6:529-35.
25. Poulaki V, Mitsiades N, Romero ME, Tsokos M. Fas-mediated apoptosis in neuroblastoma requires mitochondrial activation and is inhibited by FLICE inhibitor protein and Bcl-2. Cancer Res 2001;61:4864-72.
26. Sedlacek HH, Czech J, Naik R, et al. Flavopiridol (L86 8275; NSC 649890), a new kinase inhibitor for tumor therapy. Int J Oncol 1996;9:1143-68.
27. Patel V, Senderovicz AM, Pinto D Jr, et al. Flavopiridol, a novel cyclin-dependent kinase inhibitor, suppresses the growth of head and neck squamous cell carcinomas by inducing apoptosis. J Clin Investig 1998;102:1674-81.
28. Drees M, Dengler WA, Roth T, et al. Flavopiridol (L86-8275): selective antitumor activity in vitro and activity in vivo for prostate carcinoma cells. Clin Cancer Res 1997;3:273-9.
29. Arguello F, Alexander M, Sterry JA, et al. Flavopiridol induces apoptosis of normal lymphoid cells, causes immunosuppression, and has potent antitumor activity in vivo against human leukemia and lymphoma xenografts. Blood 1998;91:2482-90.
30. Bible KC, Kaufmann SH. Flavopiridol: a cytotoxic flavone that induces cell death in noncycling A549 human lung carcinoma cells. Cancer Res 1996;56:4856-4861.
31. Byrd JC, Shinn C, Waselenko JK, et al. Flavopiridol induces apoptosis in chronic lymphocytic leukemia cells via activation of caspase-3 without evidence of bcl-2 modulation or dependence on functional p53. Blood 1998;92:3804-16.
32. Robinson WA, Miller TL, Harrold EA, Bemis LT, Brady BM, Nelson RP. The effect of flavopiridol on the growth of p16+ and p16-melanoma cell lines. Melanoma Res 2003;13:231-8.
33. Litz J, Carlson P, Warshamana-Greene GS, Grant S, Krystal GW. Flavopiridol potently induces small cell lung cancer apoptosis during S phase in a manner that involves early mitochondrial dysfunction. Clin Cancer Res 2003;9:4586-94.
34. Bible KC, Kaufmann SH. Cytotoxic synergy between flavopiridol (NSC 649890, L86-8275) and various antineoplastic agents: the importance of sequence of administration. Cancer Res 1997;57:3375-80.
35. Motwani M, Delohery TM, Schwartz GK. Sequential dependent enhancement of caspase activation and apoptosis by flavopiridol on paclitaxel-treated human gastric and breast cancer cells. Clin Cancer Res 1999;5:1876-83.
36. Senderowicz AM. The cell cycle as a target for cancer therapy: basic and clinical findings with the small molecule inhibitors flavopiridol and UCN-01. Oncologist 2002;7(Suppl 3):12-9.
37. Schwartz GK, O'Reilly E, Ilson D, et al. Phase I study of the cyclin-dependent kinase inhibitor flavopiridol in combination with paclitaxel in patients with advanced solid tumors. J Clin Oncol 2002;20:2157-70.
38. Thomas JP, Tutsch KD, Cleary JF, et al. Phase I clinical and pharmacokinetic trial of the cyclin-dependent kinase inhibitor flavopiridol. Cancer Chemother Pharmacol 2002;50:465-72.
39. Carlson BA, Dubay MM, Sausville EA, Brizuela L, Worland PJ. Flavopiridol induces G1 arRest with inhibition of cyclin-dependent kinase (CDK) 2 and CDK4 in human breast carcinoma cells. Cancer Res 1996;56:2973-8.
40. Shapiro GI, Koestner DA, Matranga CB, Rollins BJ. Flavopiridol induces cell cycle arrest and p53-independent apoptosis in non-small cell lung cancer cell lines. Clin Cancer Res 1999;5:2925-38.
41. Parker BV, Kaur G, Nieves-Neira W, et al. Early induction of apoptosis in hematopoietic cell lines after exposure to flavopiridol. Blood 1998;91:458-65.
42. Achenbach TV, Muller R, Slater EP. Bcl-2 independence of flavopiridol-induced apoptosis. Mitochondrial depolarization in the absence of cytochrome c release. J Biol Chem 2000;275:32089-97.
43. Konig A, Schwartz GK, Mohammad RM, Al Katib A, Gabrilove JL. The novel cyclin-dependent kinase inhibitor flavopiridol downregulates Bcl-2 and induces growth arrest and apoptosis in chronic B-cell leukemia lines. Blood 1997;90:4307-12.
44. Alonso M, Tamasdan C, Miller DC, Newcomb EW. Flavopiridol induces apoptosis in glioma cell lines independent of retinoblastoma and p53 tumor suppRessor pathway alterations by a caspase-independent pathway. Mol Cancer Ther 2003;2:139-50.
45. Bogenmann E. A metastatic neuroblastoma model in SCID mice. Int J Cancer 1996;67:379-85.
46. Earnshaw WC, Martins LM, Kaufmann SH. Mammalian caspases: structure, activation, substrates, and functions during apoptosis. Annu Rev Biochem 1999;68:383-424.
47. Green DR, Reed JC. Mitochondria and apoptosis. Science (Wash DC) 1998;281:1309-12.
48. Fan L, Zhu S, Frick KK, et al. Inhibition of N-myc expression and induction of apoptosis by iron chelation in human neuroblastoma cells. Cancer Res 2001;61:1073-9.
49. Fulda S, Lutz W, Schwab M, Debatin KM. MycN sensitizes neuroblastoma cells for drug-induced apoptosis. Oncogene 1999;18:1479-86.
50. Nakamura M, Matsuo T, Stauffer J, Neckers L, Thiele CJ. Retinoic acid decreases targeting of p27 for degradation via an N-myc-dependent decrease in p27 phosphorylation and an N-myc-independent decrease in Skp2. Cell Death Differ 2003;10:230-9.
51. Galderisi U, Di Bernardo G, Cipollaro M, et al. Differentiation and apoptosis of neuroblastoma cells: role of N-myc gene product. J Cell Biochem 1999;73:97-105.
52. Thompson CB. Apoptosis in the pathogenesis and treatment of disease. Science (Wash DC) 1995;267:1456-62.
53. Johnstone RW, Ruefli AA, Lowe SW. Apoptosis: a link between cancer genetics and chemotherapy. Cell 2002;108:153-64.
54. Slee EA, Adrain C, Martin SJ. Serial killers: ordering caspase activation events in apoptosis. Cell Death Differ 1999;6:1067-74.
55. Decker RH, Dai Y, Grant S. The cyclin-dependent kinase inhibitor flavopiridol induces apoptosis in human leukemia cells (U937) through the mitochondrial rather than the receptor-mediated pathway. Cell Death Differ 2001;8:715-24.
56. Newcomb EW, Tamasdan C, Entzminger Y, et al. Flavopiridol induces mitochondrial-mediated apoptosis in murine glioma GL261 cells via release of cytochrome c and apoptosis inducing factor. Cell Cycle 2003;2:243-50.
57. Guo Y, Srinivasula SM, Druilhe A, Fernandes-Alnemri T, Alnemri ES. Caspase-2 induces apoptosis by releasing proapoptotic proteins from mitochondria. J Biol Chem 2002;277:13430-7.
58. Mancini M, Nicholson DW, Roy S, et al. The caspase-3 precursor has a cytosolic and mitochondrial distribution: implications for apoptotic signaling. J Cell Biol 1998;140:1485-95.
59. Bian X, McAllister-Lucas LM, Shao F, et al. NF-kappa B activation mediates doxorubicin-induced cell death in N-type neuroblastoma cells. J Biol Chem 2001;276:48921-9.
60. Bian X, Giordano TD, Lin HJ, Solomon G, Castle VP, Opipari AW Jr. Chemotherapy-induced apoptosis of S-type neuroblastoma cells requiRes caspase-9 and is augmented by CD95/Fas stimulation. J Biol Chem 2004;279:4663-9.
61. Bruick RK. Expression of the gene encoding the proapoptotic Nip3 protein is induced by hypoxia. Proc Natl Acad Sci USA 2000;97:9082-7.
62. Weiss WA, Aldape K, Mohapatra G, Feuerstein BG, Bishop JM. Targeted expression of MYCN causes neuroblastoma in transgenic mice. EMBO J 1997;16:2985-95.
63. Livingstone A, Mairs RJ. N-myc amplification and its relationship to experimental therapy. J Neurooncol 1997;31:33-9.